Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis

Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline

Raghu, G., Remy-Jardin, M., Richeldi, L., Thomson, C. C., Inoue, Y., Johkoh, T., Kreuter, M., Lynch, D. A., Maher, T. M., Martinez, F. J., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202202-0399st · Cited by 2,957 · see citing works

Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical Use

Bender, A. T., & Beavo, J. A. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.5 · Cited by 1,787 · see citing works

Clinical course and prediction of survival in idiopathic pulmonary fibrosis

Ley, B., Collard, H. R., & King, T. E. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201006-0894ci · Cited by 1,765 · see citing works

Integrating mechanisms of pulmonary fibrosis

Wynn, T. A. (2011) · The Journal of Experimental Medicine · doi:10.1084/jem.20110551 · Cited by 1,282 · see citing works

Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials

Calverley, P. M. A., Rabe, K. F., Goehring, U.-M., Kristiansen, S., Fabbri, L. M., & Martínez, F. J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61255-1 · Cited by 821 · see citing works

Overview of PDEs and Their Regulation

Omori, K., & Kotera, J. (2007) · Circulation Research · doi:10.1161/01.res.0000256354.95791.f1 · Cited by 797 · see citing works

Advances in targeting cyclic nucleotide phosphodiesterases

Maurice, D. H., Ke, H., Ahmad, F., Wang, Y., Chung, J. H., & Manganiello, V. C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4228 · Cited by 789 · see citing works

Mammalian Cyclic Nucleotide Phosphodiesterases: Molecular Mechanisms and Physiological Functions

Francis, S. H., Blount, M. A., & Corbin, J. D. (2011) · Physiological Reviews · doi:10.1152/physrev.00030.2010 · Cited by 644 · see citing works

Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases

Li, H., Zuo, J., & Tang, W. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01048 · Cited by 580 · see citing works

Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults

Paller, A. S., Tom, W. L., Lebwohl, M., Blumenthal, R. L., Boguniewicz, M., Call, R. S., Eichenfield, L. F., Forsha, D. W., Rees, W. C., Simpson, E. L., et al. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.05.046 · Cited by 578 · see citing works

The gene encoding phosphodiesterase 4D confers risk of ischemic stroke

Grétarsdóttir, S., Þorleifsson, G., Reynisdottir, S. T., Manolescu, A. R., Jonsdottir, S., Jónsdóttir, Þ., Gudmundsdottir, T., Bjarnadottir, S. M., Einarsson, O. B., Gudjonsdottir, H. M., et al. (2003) · Nature Genetics · doi:10.1038/ng1245 · Cited by 559 · see citing works

Structure, Localization, and Regulation of cGMP-inhibited Phosphodiesterase (PDE3)

Degerman, E., Belfrage, P., & Manganiello, V. C. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.11.6823 · Cited by 432 · see citing works

Anti-Inflammatory and Immunomodulatory Potential of the Novel PDE4 Inhibitor Roflumilast in Vitro

Hatzelmann, A., & Schudt, C. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29537-9 · Cited by 399 · see citing works

Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-α responses

Jin, S.-L. C., & Conti, M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122041599 · Cited by 368 · see citing works

Clinical and Molecular Genetics of the Phosphodiesterases (PDEs)

Azevedo, M. F., Faucz, F. R., Bimpaki, E. I., Horvath, A., Levy, I., de Alexandre, R. B., Ahmad, F., Manganiello, V. C., & Stratakis, C. A. (2013) · Endocrine Reviews · doi:10.1210/er.2013-1053 · Cited by 326 · see citing works

A Family of Human Phosphodiesterases Homologous to the Dunce Learning and Memory Gene Product of Drosophila melanogaster are Potential Targets for Antidepressant Drugs

Bolger, G. B., Michaeli, T., Martins, T., John, T. S., Steiner, B., Rodgers, L., Riggs, M. G., Wigler, M. H., & Ferguson, K. M. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.10.6558-6571.1993 · Cited by 317 · see citing works

Compartmentalized Phosphodiesterase-2 Activity Blunts β-Adrenergic Cardiac Inotropy via an NO/cGMP-Dependent Pathway

Mongillo, M., Tocchetti, C. G., Terrin, A., Lissandron, V., Cheung, Y.-F., Dostmann, W. R., Pozzan, T., Kass, D. A., Paolocci, N., Houslay, M. D., et al. (2005) · Circulation Research · doi:10.1161/01.res.0000200178.34179.93 · Cited by 279 · see citing works

Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease

Rabe, K. F. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01218.x · Cited by 272 · see citing works

Deletion of phosphodiesterase 4D in mice shortens α2-adrenoceptor–mediated anesthesia, a behavioral correlate of emesis

Robichaud, A., Stamatiou, P. B., Jin, S.-L. C., Lachance, N., MacDonald, D., Laliberté, F., Liu, S., Huang, Z., Conti, M., & Chan, C.-C. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15506 · Cited by 267 · see citing works

CD3- and CD28-Dependent Induction of PDE7 Required for T Cell Activation

Li, L., Yee, C., & Beavo, J. A. (1999) · Science · doi:10.1126/science.283.5403.848 · Cited by 259 · see citing works

Deletion of phosphodiesterase 4D in mice shortens α2-adrenoceptor–mediated anesthesia, a behavioral correlate of emesis

Robichaud, A., Stamatiou, P. B., Jin, S.-L. C., Lachance, N., Macdonald, D., Laliberté, F., Liu, S., Huang, Z., Conti, M., & Chan, C. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215506 · Cited by 259 · see citing works

Specific Role of Phosphodiesterase 4B in Lipopolysaccharide-Induced Signaling in Mouse Macrophages

Jin, S.-L. C., Lan, L., Zoudilova, M., & Conti, M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.3.1523 · Cited by 256 · see citing works

Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis

Richeldi, L., Azuma, A., Cottin, V., Hesslinger, C., Stowasser, S., Valenzuela, C., Wijsenbeek, M. S., Zoz, D. F., Voss, F., & Maher, T. M. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2201737 · Cited by 236 · see citing works

Phosphodiesterase-4D Knock-Out and RNA Interference-Mediated Knock-Down Enhance Memory and Increase Hippocampal Neurogenesis via Increased cAMP Signaling

Li, Y., Cheng, Y., Huang, Y., Conti, M., Wilson, S. P., O’Donnell, J. M., & Zhang, H. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.5236-10.2011 · Cited by 233 · see citing works

PDE10A inhibition reverses subchronic PCP‐induced deficits in attentional set‐shifting in rats

Rodefer, J. S., Murphy, E. R., & Baxter, M. G. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.03937.x · Cited by 199 · see citing works

Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2)

Crowley, J., Thaçi, D., Joly, P., Peris, K., Papp, K. A., Goncalves, J., Day, R. M., Chen, R., Shah, K., Ferrándiz, C., et al. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.01.052 · Cited by 193 · see citing works

Progression of fibrosing interstitial lung disease

Wong, A. W., Ryerson, C. J., & Guler, S. A. (2020) · Respiratory Research · doi:10.1186/s12931-020-1296-3 · Cited by 186 · see citing works

Anxiogenic-Like Behavioral Phenotype of Mice Deficient in Phosphodiesterase 4B (PDE4B)

Zhang, H., Huang, Y., Masood, A., Stolinski, L. R., Li, Y., Zhang, L., Dlaboga, D., Jin, S.-L. C., Conti, M., & O’Donnell, J. M. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301537 · Cited by 180 · see citing works

Nonredundant Function of Phosphodiesterases 4D and 4B in Neutrophil Recruitment to the Site of Inflammation

Ariga, M., Neitzert, B., Nakae, S., Mottin, G., Bertrand, C., Pruniaux, M., Jin, S.-L. C., & Conti, M. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.12.7531 · Cited by 179 · see citing works

Phosphodiesterase 4B2 Is the Predominant Phosphodiesterase Species and Undergoes Differential Regulation of Gene Expression in Human Monocytes and Neutrophils

Wang, P., Wu, P., Ohleth, K. M., Egan, R. W., & Billah, M. M. (1999) · Molecular Pharmacology · doi:10.1124/mol.56.1.170 · Cited by 173 · see citing works

Splice variants of the cyclic nucleotide phosphodiesterase PDE4D are differentially expressed and regulated in rat tissue

Richter, W., Jin, S.-L. C., & Conti, M. (2005) · Biochemical Journal · doi:10.1042/bj20050030 · Cited by 161 · see citing works

Expression of Three Isoforms of cGMP-Binding cGMP-Specific Phosphodiesterase (PDE5) in Human Penile Cavernosum

Lin, C., Lau, A., Tu, R., & Lue, T. F. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.2187 · Cited by 157 · see citing works

Absence of muscarinic cholinergic airway responses in mice deficient in the cyclic nucleotide phosphodiesterase PDE4D

Hansen, G., Jin, S.-L. C., Umetsu, D. T., & Conti, M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.12.6751 · Cited by 154 · see citing works

Suncus murinus: A new experimental model in emesis research

Ueno, S., Matsuki, N., & Saitō, H. (1987) · Life Sciences · doi:10.1016/0024-3205(87)90229-3 · Cited by 154 · see citing works

The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT–dependent apoptosis in diffuse large B-cell lymphoma

Smith, P. G., Wang, F., Wilkinson, K., Savage, K. J. J., Klein, U., Neuberg, D. S., Bollag, G. E., Shipp, M. A., & Aguiar, R. C. T. (2004) · Blood · doi:10.1182/blood-2004-01-0240 · Cited by 144 · see citing works

PDE4D plays a critical role in the control of airway smooth muscle contraction

Méhats, C., Jin, S.-L. C., Wahlstrom, J., Law, E. C., Umetsu, D. T., & Conti, M. (2003) · The FASEB Journal · doi:10.1096/fj.03-0274com · Cited by 142 · see citing works

Phosphodiesterase 1B Knock-Out Mice Exhibit Exaggerated Locomotor Hyperactivity and DARPP-32 Phosphorylation in Response to Dopamine Agonists and Display Impaired Spatial Learning

Reed, T. M., Repaske, D. R., Snyder, G. L., Greengard, P., & Vorhees, C. V. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-12-05188.2002 · Cited by 141 · see citing works

Expression and regulation of human and rat phosphodiesterase type IV isogenes

Engels, P., Fichtel, K., & Lübbert, H. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)00788-8 · Cited by 141 · see citing works

Phosphodiesterase 8B Gene Variants Are Associated with Serum TSH Levels and Thyroid Function

Arnaud-Lopez, L., Usala, G., Ceresini, G., Mitchell, B. D., Pilia, M. G., Piras, M. G., Sestu, N., Maschio, A., Busonero, F., Albai, G., et al. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2008.04.019 · Cited by 139 · see citing works

Phosphodiesterases as therapeutic targets for respiratory diseases

Zuo, H., Cattani‐Cavalieri, I., Musheshe, N., Nikolaev, V. O., & Schmidt, M. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.02.002 · Cited by 139 · see citing works

BI 1015550 is a PDE4B Inhibitor and a Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis

Herrmann, F. E., Hesslinger, C., Wollin, L., & Nickolaus, P. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.838449 · Cited by 137 · see citing works

Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease

Giembycz, M. A. (2001) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.10.7.1361 · Cited by 135 · see citing works

Phosphodiesterase Type 3A Regulates Basal Myocardial Contractility Through Interacting With Sarcoplasmic Reticulum Calcium ATPase Type 2a Signaling Complexes in Mouse Heart

Beca, S., Ahmad, F., Shen, W., Liu, J., Makary, S., Polidovitch, N., Sun, J., Hockman, S. C., Chung, Y. W., Movsesian, M. A., et al. (2012) · Circulation Research · doi:10.1161/circresaha.111.300003 · Cited by 135 · see citing works

A low-Km, rolipram-sensitive, cAMP-specific phosphodiesterase from human brain. Cloning and expression of cDNA, biochemical characterization of recombinant protein, and tissue distribution of mRNA.

McLaughlin, M. M., Cieslinski, L. B., Burman, M., Torphy, T. J., & Livi, G. P. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)53275-0 · Cited by 128 · see citing works

p75 neurotrophin receptor regulates tissue fibrosis through inhibition of plasminogen activation via a PDE4/cAMP/PKA pathway

Sachs, B. D., Baillie, G. S., McCall, J. R., Passino, M. A., Schachtrup, C., Wallace, D. A., Dunlop, A. J., MacKenzie, K. F., Klußmann, E., Lynch, M. J., et al. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200701040 · Cited by 126 · see citing works

Cyclic Nucleotide Phosphodiesterase 1C Promotes Human Arterial Smooth Muscle Cell Proliferation

Rybalkin, S. D., Rybalkina, I. G., Beavo, J. A., & Bornfeldt, K. (2002) · Circulation Research · doi:10.1161/hh0202.104108 · Cited by 123 · see citing works

Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers

Barber, R., Baillie, G. S., Bergmann, R., Shepherd, M. C., Sepper, R., Houslay, M. D., & Heeke, G. V. (2004) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00384.2003 · Cited by 121 · see citing works

Phosphodiesterase 4D is required for β 2 adrenoceptor subtype-specific signaling in cardiac myocytes

Xiang, Y. K., Naro, F., Zoudilova, M., Jin, S.-L. C., Conti, M., & Kobilka, B. K. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405263102 · Cited by 121 · see citing works

Role of Nuclear Ca 2+ /Calmodulin-Stimulated Phosphodiesterase 1A in Vascular Smooth Muscle Cell Growth and Survival

Nagel, D. J., Aizawa, T., Jeon, K., Liu, W., Mohan, A. M., Wei, H., Miano, J. M., Florio, V. A., Gao, P., Korshunov, V. A., et al. (2006) · Circulation Research · doi:10.1161/01.res.0000215576.27615.fd · Cited by 121 · see citing works

Inhaled Phosphodiesterase 4 (PDE4) Inhibitors for Inflammatory Respiratory Diseases

Phillips, J. E. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00259 · Cited by 119 · see citing works

Roflumilast, a phosphodiesterase 4 inhibitor, alleviates bleomycin‐induced lung injury

Cortijo, J., Iranzo, A., Milara, X., Mata, M., Cerdá‐Nicolás, M., Ruiz‐Saurí, A., Tenor, H., Hatzelmann, A., & Morcillo, E. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00041.x · Cited by 114 · see citing works

Cilomilast for COPD

Rennard, S. I., Schachter, N., Strek, M. E., Rickard, K., & Amit, O. (2006) · CHEST Journal · doi:10.1378/chest.129.1.56 · Cited by 113 · see citing works

Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-4B (PDE4B) enzyme

Siuciak, J., McCarthy, S. A., Chapin, D., & Martin, A. N. (2008) · Psychopharmacology · doi:10.1007/s00213-007-1014-6 · Cited by 111 · see citing works

Phosphodiesterase 4D Forms a cAMP Diffusion Barrier at the Apical Membrane of the Airway Epithelium

Barnes, A. P., Livera, G., Huang, P., Sun, C., O’Neal, W. K., Conti, M., Stutts, M. J., & Milgram, S. L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407521200 · Cited by 111 · see citing works

Expression of cGMP-Specific Phosphodiesterase 9A mRNA in the Rat Brain

Andreeva, S. G., Dikkes, P., Epstein, P. M., & Rosenberg, P. A. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-22-09068.2001 · Cited by 107 · see citing works

Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages

Maier, C., Ramming, A., Bergmann, C., Weinkam, R., Kittan, N. A., Schett, G. A., Distler, J. H. W., & Beyer, C. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210189 · Cited by 103 · see citing works

Phosphodiesterase 4B is essential for TH2-cell function and development of airway hyperresponsiveness in allergic asthma

Jin, S.-L. C., Goya, S., Nakae, S., Wang, D., Bruss, M. D., Hou, C., Umetsu, D. T., & Conti, M. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.08.014 · Cited by 99 · see citing works

Inhibition of phosphodiesterase‐4 attenuates murine ulcerative colitis through interference with mucosal immunity

Li, H., Fan, C., Feng, C., Wu, Y., Lu, H., He, P., Yang, X., Zhu, F., Qi, Q., Gao, Y., et al. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14667 · Cited by 98 · see citing works

Modulation of Leydig cell function by cyclic nucleotide phosphodiesterase 8A

Vasta, V., Shimizu‐Albergine, M., & Beavo, J. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609483103 · Cited by 91 · see citing works

Inhibition of phoshodiesterase type 2 or type 10 reverses object memory deficits induced by scopolamine or MK-801

Reneerkens, O. A. H., Rutten, K., Bollen, E., Hage, T., Blokland, A., Steinbusch, H. W. M., & Prickaerts, J. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.08.019 · Cited by 90 · see citing works

The Efficacy and Safety of Cilomilast in COPD

Rennard, S., Knobil, K., Rabe, K., Morris, A. N., Schachter, N. E., Locantore, N., Canonica, W., Zhu, Y.-J., & Barnhart, F. (2012) · Drugs · doi:10.2165/0003495-200868002-00002 · Cited by 87 · see citing works

Identification of two splice variant forms of type-IVB cyclic AMP phosphodiesterase, DPD (rPDE-IVB1) and PDE-4 (rPDE-IVB2) in brain: selective localization in membrane and cytosolic compartments and differential expression in various brain regions

Lobban, M. D., Shakur, Y., Beattie, J., & Houslay, M. D. (1994) · Biochemical Journal · doi:10.1042/bj3040399 · Cited by 85 · see citing works

Activation of PDE10 and PDE11 Phosphodiesterases

Jäger, R., Russwurm, C., Schwede, F., Genieser, H., Koesling, D., & Russwurm, M. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.263806 · Cited by 84 · see citing works

Differential Expression of the Cyclic GMP-stimulated Phosphodiesterase PDE2A in Human Venous and Capillary Endothelial Cells

Sadhu, K., Hensley, K. M., Florio, V., & Wolda, S. L. (1999) · Journal of Histochemistry & Cytochemistry · doi:10.1177/002215549904700707 · Cited by 80 · see citing works

Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1–3 pooled analysis

Kavanaugh, A., Gladman, D. D., Edwards, C. J., Schett, G. A., Guérette, B., Delev, N. G., Teng, L. L., Paris, M. M., & Mease, P. J. (2019) · Arthritis Research & Therapy · doi:10.1186/s13075-019-1901-3 · Cited by 80 · see citing works

Emerging drug delivery strategies for idiopathic pulmonary fibrosis treatment

Ghumman, M., Dhamecha, D. L., Gonsalves, A., Fortier, L., Sorkhdini, P., Zhou, Y., & Menon, J. U. (2021) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2021.03.017 · Cited by 79 · see citing works

Phosphodiesterase expression in human epithelial cells

Wright, L. C., Seybold, J., Robichaud, A., Adcock, I. M., & Barnes, P. J. (1998) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.1998.275.4.l694 · Cited by 78 · see citing works

Presence of Cyclic Nucleotide Phosphodiesterases PDE1A, Existing as a Stable Complex with Calmodulin, and PDE3A in Human Spermatozoa1

Lefièvre, L., de Lamirande, E., & Gagnon, C. (2002) · Biology of Reproduction · doi:10.1095/biolreprod67.2.423 · Cited by 74 · see citing works

Molecular cloning and functional expression in yeast of a human cAMP‐specific phosphodiesterase subtype (PDE IV‐C)

Engels, P., Sullivan, M., Müller, T. M., & Lübbert, H. (1995) · FEBS Letters · doi:10.1016/0014-5793(94)01460-i · Cited by 74 · see citing works

Molecular Cloning, Genomic Positioning, Promoter Identification, and Characterization of the Novel Cyclic AMP-Specific Phosphodiesterase PDE4A10

Rena, G., Begg, F., Ross, A. H., MacKenzie, C., McPhee, I., Campbell, L., Huston, E., Sullivan, M., & Houslay, M. D. (2001) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12557-6 · Cited by 72 · see citing works

Downregulation of Brain Phosphodiesterase Type IV Measured with 11C-(R)-Rolipram Positron Emission Tomography in Major Depressive Disorder

Fujita, M., Hines, C. S., Zoghbi, S. S., Mallinger, A. G., Dickstein, L. P., Liow, J., Zhang, Y., Pike, V. W., Drevets, W. C., Innis, R. B., et al. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.04.030 · Cited by 69 · see citing works

PDE4B5, a Novel, Super-Short, Brain-Specific cAMP Phosphodiesterase-4 Variant Whose Isoform-Specifying N-Terminal Region Is Identical to That of cAMP Phosphodiesterase-4D6 (PDE4D6)

Cheung, Y.-F., Kan, Z., Garrett-Engele, P. W., Gall, I., Murdoch, H., Baillie, G. S., Camargo, L. M., Johnson, J. M., Houslay, M. D., & Castle, J. C. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.122218 · Cited by 64 · see citing works

Phosphodiesterase type 5 (PDE5) inhibition improves object recognition memory: Indications for central and peripheral mechanisms

Reneerkens, O. A. H., Rutten, K., Akkerman, S., Blokland, A., Shaffer, C. L., Menniti, F. S., Steinbusch, H. W. M., & Prickaerts, J. (2012) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2012.02.008 · Cited by 64 · see citing works

The unique N‐terminal domain of the cAMP phosphodiesterase PDE4D4 allows for interaction with specific SH3 domains

Beard, M., O’Connell, J. C., Bolger, G. B., & Houslay, M. D. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)01335-6 · Cited by 64 · see citing works

Phosphodiesterase 4 inhibition reduces lung fibrosis following targeted type II alveolar epithelial cell injury

Sisson, T. H., Christensen, P. J., Muraki, Y., Dils, A. J., Chibucos, L. N., Subbotina, N., Tohyama, K., Horowitz, J. C., Matsuo, T., Bailie, M. B., et al. (2018) · Physiological Reports · doi:10.14814/phy2.13753 · Cited by 62 · see citing works

Phosphodiesterase 8 (PDE8) regulates chemotaxis of activated lymphocytes

Dong, H., Osmanova, V., Epstein, P. M., & Brocke, S. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.04.143 · Cited by 61 · see citing works

The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease

Cazzola, M., Calzetta, L., Rogliani, P., & Matera, M. G. (2016) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2016.1184642 · Cited by 60 · see citing works

Molecular cloning and subcellular distribution of the novel PDE4B4 cAMP-specific phosphodiesterase isoform

Shepherd, M. C., McSorley, T., Olsen, A. E., Johnston, L. A., Thomson, N. C., Baillie, G. S., Houslay, M. D., & Bolger, G. B. (2003) · Biochemical Journal · doi:10.1042/bj20021082 · Cited by 60 · see citing works

Mice deficient in phosphodiesterase-4A display anxiogenic-like behavior

Hansen, R., Conti, M., & Zhang, H. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3480-y · Cited by 59 · see citing works

Identification and Characterization of PDE4A11, a Novel, Widely Expressed Long Isoform Encoded by the Human PDE4A cAMP Phosphodiesterase Gene

Wallace, D. A., Johnston, L. A., Huston, E., MacMaster, D., Houslay, T. M., Cheung, Y.-F., Campbell, L., Millen, J. E., Smith, R. A. J., Gall, I., et al. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.009423 · Cited by 59 · see citing works

Dual inhibitor of PDE7 and GSK-3 – VP1.15 acts as antipsychotic and cognitive enhancer in C57BL/6J mice

Lipina, T. V., Palomo, V., Gil, C., Martı́nez, A., & Roder, J. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.06.032 · Cited by 58 · see citing works

Phosphodiesterase-4 inhibition attenuates pulmonary inflammation in neonatal lung injury

de Visser, Y. P., Walther, F. J., Laghmani, E. H., van Wijngaarden, S., Nieuwland, K., & Wagenaar, G. T. M. (2007) · European Respiratory Journal · doi:10.1183/09031936.00071307 · Cited by 57 · see citing works

Cloning and characterization of novel PDE4D isoforms PDE4D6 and PDE4D7

Wang, D., Deng, C., Bugaj‐Gaweda, B., Kwan, M. F., Gunwaldsen, C., Leonard, C. J., Xin, X., Hu, Y., Unterbeck, A., & Vivo, M. D. (2003) · Cellular Signalling · doi:10.1016/s0898-6568(03)00042-1 · Cited by 57 · see citing works

The differential impact of PDE4 subtypes in human lung fibroblasts on cytokine‐induced proliferation and myofibroblast conversion

Selige, J., Hatzelmann, A., & Dunkern, T. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.22529 · Cited by 56 · see citing works

Mangostanin Derivatives as Novel and Orally Active Phosphodiesterase 4 Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis with Improved Safety

Huang, Y., Deng, J., Tian, Y., Liang, J., Xie, X. S., Huang, Y., Zhu, J., Zhu, Z., Zhou, Q., He, X., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01085 · Cited by 52 · see citing works

PDE4 and PDE5 regulate cyclic nucleotides relaxing effects in human umbilical arteries

Santos-Silva, A. J., Cairrão, E., Morgado, M., Álvarez, E., & Verde, I. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.12.017 · Cited by 52 · see citing works

Evaluation of fibrosis in precision-cut tissue slices

Westra, I. M., Pham, B. T., Groothuis, G. M. M., & Olinga, P. (2012) · Xenobiotica · doi:10.3109/00498254.2012.723151 · Cited by 49 · see citing works

Hypoxia-induced remodelling of PDE4 isoform expression and cAMP handling in human pulmonary artery smooth muscle cells

Millen, J. E., MacLean, M. R., & Houslay, M. D. (2006) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2006.01.006 · Cited by 48 · see citing works

Regulatory roles of adenylate cyclase and cyclic nucleotide phosphodiesterases 1 and 4 in interleukin-13 production by activated human T cells

Kanda, N., & Watanabe, S. (2001) · Biochemical Pharmacology · doi:10.1016/s0006-2952(01)00688-8 · Cited by 46 · see citing works

Inhibition of phosphodiesterase type 9 reduces obesity and cardiometabolic syndrome in mice

Mishra, S., Sadagopan, N., Sadagopan, N., Dunkerly-Eyring, B. L., Rodriguez, S., Sarver, D. C., Murphy, S. A., Knútsdóttir, H., Knútsdóttir, H., Jani, V., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci148798 · Cited by 46 · see citing works

Role of PDE3A in regulation of cell cycle progression in mouse vascular smooth muscle cells and oocytes: implications in cardiovascular diseases and infertility

Begum, N., Shen, W., & Manganiello, V. (2011) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2011.10.006 · Cited by 46 · see citing works

Treatment with the phosphodiesterase type-4 inhibitor rolipram fails to inhibit blood—brain barrier disruption in multiple sclerosis

Bielekova, B., Richert, N. D., Howard, T., Packer, A. N., Blevins, G., Ohayon, J. M., McFarland, H. F., Stürzebecher, C.-S., & Martinꝉ, R. (2009) · Multiple Sclerosis Journal · doi:10.1177/1352458509345903 · Cited by 45 · see citing works

Tanimilast, A Novel Inhaled Pde4 Inhibitor for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease

Facchinetti, F., Civelli, M., Singh, D., Papi, A. A., Emirova, A., & Govoni, M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.740803 · Cited by 44 · see citing works

Cyclic Nucleotide Phosphodiesterase 3 Signaling Complexes

Ahmad, F., Degerman, E., & Manganiello, V. (2012) · Hormone and Metabolic Research · doi:10.1055/s-0032-1312646 · Cited by 42 · see citing works

A novel phosphodiesterase 4 inhibitor, AA6216, reduces macrophage activity and fibrosis in the lung

Matsuhira, T., Nishiyama, O., Tabata, Y., Kaji, C., Kubota-Ishida, N., Chiba, Y., Sano, H., Iwanaga, T., & Tohda, Y. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173508 · Cited by 41 · see citing works

Mutation in Rod PDE6 Linked to Congenital Stationary Night Blindness Impairs the Enzyme Inhibition by Its γ-Subunit

Muradov, K. G., Granovsky, A. E., & Artemyev, N. O. (2003) · Biochemistry · doi:10.1021/bi027095x · Cited by 38 · see citing works

4D or not 4D – the emetogenic basis of PDE4 inhibitors uncovered?

Giembycz, M. A. (2002) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(02)02089-8 · Cited by 38 · see citing works

Pharmacological Inhibition of Phosphodiesterase 4 Triggers Ovulation in Follicle-Stimulating Hormone-Primed Rats

McKenna, S. D., Pietropaolo, M., Tos, E. G., Clark, A. S., Fischer, D. J., Kagan, D., Bao, B., Chedrese, P. J., & Palmer, S. S. (2004) · Endocrinology · doi:10.1210/en.2004-0562 · Cited by 35 · see citing works

Correlation between emetic effect of phosphodiesterase 4 inhibitors and their occupation of the high-affinity rolipram binding site in Suncus murinus brain

Hirose, R., Manabe, H., Nonaka, H., Yanagawa, K., Akuta, K., Sato, S., Ohshima, E., & Ichimura, M. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.06.045 · Cited by 34 · see citing works

Targeted Treatments for Chronic Obstructive Pulmonary Disease (COPD) Using Low-Molecular-Weight Drugs (LMWDs)

Ti, H., Zhou, Y., Liang, X., Li, R., Ding, K., & Zhao, X. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01520 · Cited by 32 · see citing works

Apremilast for oral ulcers associated with active Behçet's syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial

Hatemi, G., Mahr, A., Takeno, M., ‍Kim, D. Y., Saadoun, D., Di̇reskeneli̇, H., Melikoğlu, M., Cheng, S., McCue, S., Paris, M. M., et al. (2021) · Clinical and Experimental Rheumatology · doi:10.55563/clinexprheumatol/ra8ize · Cited by 32 · see citing works

Bioavailability of testosterone enanthate dependent on genetic variation in the phosphodiesterase 7B but not on the uridine 5′-diphospho-glucuronosyltransferase (UGT2B17) gene.

Ekström, L., Schulze, J. J., Guillemette, C., Bélanger, A., & Rane, A. (2011) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e328344c5c6 · Cited by 31 · see citing works

Phosphodiesterase 4 inhibitor and phosphodiesterase 5 inhibitor combination therapy has antifibrotic and anti‐inflammatory effects in mdx mice with Duchenne muscular dystrophy

Nio, Y., Tanaka, M., Hirozane, Y., Muraki, Y., Okawara, M., Hazama, M., & Matsuo, T. (2017) · The FASEB Journal · doi:10.1096/fj.201700249r · Cited by 31 · see citing works

cGMP‐dependent protein kinase II and aldosterone secretion

Spießberger, B., Bernhard, D., Herrmann, S., Feil, S. C., Werner, C. G., Luppa, P. B., & Hofmann, F. B. (2009) · FEBS Journal · doi:10.1111/j.1742-4658.2008.06839.x · Cited by 30 · see citing works

The Long and Short of Vascular Smooth Muscle Phosphodiesterase-4 As a Putative Therapeutic Target

Houslay, M. D. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.015719 · Cited by 29 · see citing works

Human PDE4A8, a novel brain-expressed PDE4 cAMP-specific phosphodiesterase that has undergone rapid evolutionary change

MacKenzie, K. F., Topping, E. C., Bugaj‐Gaweda, B., Deng, C., Cheung, Y.-F., Olsen, A. E., Stockard, C. R., Smoot, L. H. M., Baillie, G. S., Grizzle, W. E., et al. (2008) · Biochemical Journal · doi:10.1042/bj20071251 · Cited by 28 · see citing works

Crisaborole Ointment Improves Quality of Life of Patients with Mild to Moderate Atopic Dermatitis and Their Families

Simpson, E. L., Paller, A. S., Boguniewicz, M., Eichenfield, L. F., Feldman, S. R., Silverberg, J. I., Chamlin, S. L., & Zane, L. T. (2018) · Dermatology and Therapy · doi:10.1007/s13555-018-0263-0 · Cited by 27 · see citing works

Phase I studies of BI 1015550, a preferential phosphodiesterase 4B inhibitor, in healthy males and patients with idiopathic pulmonary fibrosis

Maher, T. M., Schlecker, C., Luedtke, D., Bossert, S., Zoz, D. F., & Schultz, A. (2022) · ERJ Open Research · doi:10.1183/23120541.00240-2022 · Cited by 26 · see citing works

Phosphodiesterases and regulation of female reproductive function

Conti, M. (2011) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2011.10.004 · Cited by 22 · see citing works

Role of cGMP in Sildenafil-Induced Activation of Endothelial Ca(2+)-Activated K(+) Channels

Luedders, D. W., Münz, B., Li, F., Rueckleben, S., Tillmanns, H., Waldecker, B., Wiecha, J., Erdoğan, A., Schaefer, C. A., & Kuhlmann, C. R. W. (2006) · Journal of Cardiovascular Pharmacology · doi:10.1097/01.fjc.0000206438.35477.f2 · Cited by 21 · see citing works

Regulation of the pro-inflammatory cytokine osteopontin by GIP in adipocytes – A role for the transcription factor NFAT and phosphodiesterase 3B

Omar, B. A., Banke, E., Guirguis, E., Åkesson, L., Manganiello, V. C., Lyssenko, V., Groop, L., Gomez, M. F., & Degerman, E. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.07.157 · Cited by 20 · see citing works

The role of PDE4 in pulmonary inflammation and goblet cell hyperplasia in allergic rats

Tang, H., Chen, J., Xie, Q.-M., Zheng, X., Zhu, Y.-L., Adcock, I. M., & Wang, X. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2005.12.009 · Cited by 17 · see citing works

Selective breeding of house musk shrew (Suncus murinus) lines in relation to emesis induced by veratrine sulfate.

Ebukuro, S., Wakana, S., Hioki, K., & Nomura, T. (2000) · PubMed · Cited by 15 · see citing works

Neuronal Nitric Oxide Synthase Supports Renin Release During Sodium Restriction Through Inhibition of Phosphodiesterase 3

Sällström, J., Jensen, B. L., Skøtt, O., Gao, X., & Persson, A. E. G. (2010) · American Journal of Hypertension · doi:10.1038/ajh.2010.153 · Cited by 13 · see citing works

Phosphodiesterase Type 4D Gene Polymorphism: Association with the Response to Short-Acting Bronchodilators in Paediatric Asthma Patients

Labuda, M., Laberge, S., Brière, J., Bérubé, D., Beaulieu, P., Pastinen, T., & Krajinović, M. (2011) · Mediators of Inflammation · doi:10.1155/2011/301695 · Cited by 12 · see citing works

Inhibition of phosphodiesterase 11 (PDE11) impacts on sperm quality

Pomara, G., & Morelli, G. (2005) · International Journal of Impotence Research · doi:10.1038/sj.ijir.3901304 · Cited by 11 · see citing works

Greasing the protein biosynthesis machinery of photoreceptor neurons

Christiansen, J. R., & Ramamurthy, V. (2012) · Cellular Logistics · doi:10.4161/cl.19804 · Cited by 9 · see citing works

Assays for Cyclic Nucleotide‐Specific Phosphodiesterases (PDEs) in the Central Nervous System (PDE1, PDE2, PDE4, and PDE10)

Deng, C., Wang, D., Bugaj‐Gaweda, B., & Vivo, M. D. (2007) · Current Protocols in Neuroscience · doi:10.1002/0471142301.ns0721s38 · Cited by 7 · see citing works

NO-mediated cGMP synthesis in cultured cholinergic neurons from the basal forebrain of the fetal rat

de Vente, J., Abildayeva, K., van de Waarenburg, M. P. H., Ittersum, M. M., Steinbusch, H. W. M., & Mulder, M. T. (2008) · Brain Research · doi:10.1016/j.brainres.2008.03.089 · Cited by 5 · see citing works

The phosphodiesterase 4 inhibitor AA6216 suppresses activity of fibrosis-specific macrophages

Matsuhira, T., Nishiyama, O., Tabata, Y., Kurashimo, S., Sano, H., Iwanaga, T., & Tohda, Y. (2021) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2021.101118 · Cited by 4 · see citing works

Current and Future Treatment Landscape for Idiopathic Pulmonary Fibrosis

Bonella, F., Spagnolo, P., & Ryerson, C. J. (2023) · Drugs · doi:10.1007/s40265-023-01950-0 · Cited by 188 · see citing works

Targeting Fibrosis: From Molecular Mechanisms to Advanced Therapies

Di, X., Li, Y., Wei, J., Li, T., & Liao, B. (2024) · Advanced Science · doi:10.1002/advs.202410416 · Cited by 83 · see citing works

Systemic sclerosis interstitial lung disease: unmet needs and potential solutions

Liakouli, V., Ciancio, A., Galdo, F. D., Giacomelli, R., & Ciccia, F. (2023) · Nature Reviews Rheumatology · doi:10.1038/s41584-023-01044-x · Cited by 62 · see citing works

Next Generation PDE4 Inhibitors that Selectively Target PDE4B/D Subtypes: A Narrative Review

Blauvelt, A., Langley, R. G. B., Gordon, K. B., Silverberg, J. I., Eyerich, K., Sommer, M. O. A., Felding, J., & Warren, R. B. (2023) · Dermatology and Therapy · doi:10.1007/s13555-023-01054-3 · Cited by 57 · see citing works

Insights into the Cellular and Molecular Mechanisms behind the Antifibrotic Effects of Nerandomilast

Reininger, D., Wolf, F., Mayr, C. H., Wespel, S. L., Laufhaeger, N., Geillinger‐Kästle, K. E., Dick, A., Gantner, F., Nickolaus, P., & Herrmann, F. E. (2025) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2024-0614oc · Cited by 54 · see citing works

PDE4B inhibition by nerandomilast: Effects on lung fibrosis and transcriptome in fibrotic rats and on biomarkers in human lung epithelial cells

Reininger, D., Fundel‐Clemens, K., Mayr, C. H., Wollin, L., Laemmle, B., Quast, K., Nickolaus, P., & Herrmann, F. E. (2024) · British Journal of Pharmacology · doi:10.1111/bph.17303 · Cited by 48 · see citing works

Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF)

Richeldi, L., Azuma, A., Cottin, V., Kreuter, M., Maher, T. M., Martínez, F. J., Oldham, J. M., Valenzuela, C., Gordat, M., Liu, Y., et al. (2023) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2022-001563 · Cited by 43 · see citing works

Exploring the Therapeutic Landscape: A Narrative Review on Topical and Oral Phosphodiesterase-4 Inhibitors in Dermatology

Carmona‐Rocha, E., Rusiñol, L., & Puig, L. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17010091 · Cited by 32 · see citing works

Emerging therapies for the treatment of systemic sclerosis

Distler, J. H. W., Kuwana, M., Assassi, S., & Denton, C. P. (2025) · Nature Reviews Rheumatology · doi:10.1038/s41584-025-01294-x · Cited by 25 · see citing works

Nerandomilast Improves Bleomycin-Induced Systemic Sclerosis-Associated Interstitial Lung Disease in Mice by Regulating the TGF-β1 Pathway

Liu, Y., Liu, Z., Li, X., Li, W., Yang, Z., Jiao, R., Wang, Q., Meng, L., Zhang, T., Liu, J., et al. (2024) · Inflammation · doi:10.1007/s10753-024-02153-9 · Cited by 24 · see citing works

Structural insights into the lead identification of sub-type selective PDE4B inhibitors from plant bioactive molecule analogues

Sharma, B., & Purohit, R. (2023) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2023.123039 · Cited by 24 · see citing works

Highlights on Future Treatments of IPF: Clues and Pitfalls

Libra, A., Sciacca, E., Muscato, G., Sambataro, G., Spicuzza, L., & Vancheri, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158392 · Cited by 22 · see citing works

The role of fibroblast-neutrophil crosstalk in the pathogenesis of inflammatory diseases: a multi-tissue perspective

Cai, C., Guan, L., Wang, C., Hu, R., Ou, L., & Jiang, Q. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1588667 · Cited by 22 · see citing works

Rationale for phosphodiesterase-4 inhibition as a treatment strategy for interstitial lung diseases associated with rheumatic diseases

Aringer, M., Distler, O., Hoffmann‐Vold, A., Kuwana, M., Prosch, H., & Volkmann, E. R. (2024) · RMD Open · doi:10.1136/rmdopen-2024-004704 · Cited by 21 · see citing works

Pathological mechanisms and novel drug targets in fibrotic interstitial lung disease

Nishioka, Y., Araya, J., Tanaka, Y., & Kumanogoh, A. (2024) · Inflammation and Regeneration · doi:10.1186/s41232-024-00345-2 · Cited by 18 · see citing works

Potential of phosphodiesterase 4B inhibition in the treatment of progressive pulmonary fibrosis

Keith, R. C., & Nambiar, A. M. (2025) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666241309795 · Cited by 17 · see citing works

Evidence from recent clinical trials in fibrotic interstitial lung diseases

Cottin, V., & Valenzuela, C. (2024) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001089 · Cited by 16 · see citing works

Design of CONQUEST, a novel, randomized, placebo-controlled, Phase 2b platform clinical trial to investigate new treatments for patients with early active systemic sclerosis with interstitial lung disease

Khanna, D., Evnin, L. B., Assassi, S., Benton, W. W., Gordon, G. A., Maslova, K., Steffgen, J., & Maher, T. M. (2024) · Journal of Scleroderma and Related Disorders · doi:10.1177/23971983241278079 · Cited by 16 · see citing works

Systemic sclerosis: pathogenic mechanisms and their implications for treatment

Lescoat, A., Lecureur, V., Gudjonsson, J. E., & Khanna, D. (2025) · Seminars in Immunopathology · doi:10.1007/s00281-025-01065-6 · Cited by 14 · see citing works

Immunopathogenic Mechanisms in Connective Tissue Disease-Associated Interstitial Lung Disease: Incessant Loop of Immunity to Fibrosis

Lee, J. H., Jang, J. H., Lee, S., & Her, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262412126 · Cited by 14 · see citing works

Novel therapeutic strategies and drugs for idiopathic pulmonary fibrosis

Shi, Z., Zhou, M., Zhai, J., Sun, J., & Wang, X. (2024) · Archiv der Pharmazie · doi:10.1002/ardp.202400192 · Cited by 14 · see citing works

Unmet needs and emerging pharmacotherapies for autoimmune connective tissue disease-associated interstitial lung diseases

Kondoh, Y., Fujii, T., Inoue, Y., & Atsumi, T. (2025) · Autoimmunity Reviews · doi:10.1016/j.autrev.2025.103900 · Cited by 13 · see citing works

Mechanistic basis for the antifibrotic actions of cAMP-based therapies

Peters-Golden, M. L., & Fortier, S. M. (2026) · European Respiratory Review · doi:10.1183/16000617.0265-2025 · Cited by 12 · see citing works

Exploring therapeutic targets for molecular therapy of idiopathic pulmonary fibrosis

Li, Y., Jiang, C., Zhu, W., Lu, S., Yu, H., & Meng, L. (2024) · Science Progress · doi:10.1177/00368504241247402 · Cited by 10 · see citing works

Neutrophil and Endothelial Cell Membranes Coassembled Roflumilast Nanoparticles Attenuate Myocardial Ischemia/Reperfusion Injury

Tan, Y. C., Wang, X., Gu, Y. L., Bao, X., Lu, H., Sun, X., Kang, L., & Xu, B. (2024) · Nanomedicine · doi:10.2217/nnm-2023-0313 · Cited by 9 · see citing works

Spatial Transcriptomic Profiling of Human Saphenous Vein Exposed to Ex Vivo Arterial Haemodynamics—Implications for Coronary Artery Bypass Graft Patency and Vein Graft Disease

McQueen, L. W., Ladak, S. S., Layton, G. R., Wozniak, M. J., Solomon, C. U., El‐Dean, Z., Murphy, G. J., & Zakkar, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910368 · Cited by 9 · see citing works

Idiopathic Pulmonary Fibrosis, Today and Tomorrow: Certainties and New Therapeutic Horizons

Giulianelli, G., Cocconcelli, E., Fiorentù, G., Bernardinello, N., Balestro, E., & Spagnolo, P. (2025) · Pulmonary Therapy · doi:10.1007/s41030-025-00296-0 · Cited by 9 · see citing works

Nerandomilast, a PDE4B inhibitor, alleviates silica‐induced lung inflammation and fibrosis by inhibition of NLRP3 inflammasome and TGF‐β/Smad signalling

Wang, Y., Sun, D., Dilixiati, N., Wang, D., Song, Y., & Ye, Q. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70240 · Cited by 9 · see citing works

Ensifentrine: a novel approach to redefining COPD management and implications for additional respiratory diseases

Sciurba, F. C., Jia, S., & Subramanian, S. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2491515 · Cited by 8 · see citing works

Development of a Scalable Asymmetric Process for the Synthesis of Selective PDE4B Inhibitor Nerandomilast (BI 1015550)

Frutos, R. P., Tampone, T. G., Gerstmann, F., Weber, D., Brodmann, T., Hagenkötter, R., Abella, J., Yang, B., Mulder, J. A., Rodrı́guez, S., et al. (2024) · Organic Process Research & Development · doi:10.1021/acs.oprd.4c00309 · Cited by 7 · see citing works

Pharmacological inhibition of Epac1 protects against pulmonary fibrosis by blocking FoxO3a neddylation

Jankowski, K., Lemay, S.-E. S., Lozano‐Ojalvo, D., Pérez‐Rodríguez, L., Sauvaget, M., Breuils‐Bonnet, S., Formoso, K., Jagana, V., Ochoa, M. T., Zhang, S., et al. (2025) · European Respiratory Journal · doi:10.1183/13993003.02250-2024 · Cited by 7 · see citing works

A phosphodiesterase-4 inhibitor reduces lung inflammation and fibrosis in a hamster model of SARS-CoV-2 infection

Kolloli, A., Ramasamy, S., Kumar, R., Nisa, A., Kaplan, G., & Subbian, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1270414 · Cited by 7 · see citing works

Nanodrug delivery system for precision treatment of pulmonary fibrosis

Yi, X., Zhang, X., Guan, Y., Sha, Y., Cheng, X., Lee, Y. C., & Yuan, W. (2025) · Precision medicine and engineering. · doi:10.1016/j.preme.2025.100025 · Cited by 6 · see citing works

Phosphodiesterase 4B (PDE4B) inhibitors and their applications in recent years (2014 to early 2025)

Zhang, J., Zhai, J., Liu, H., Liu, H., Sun, B., Gao, J., & Sang, F. (2025) · Molecular Diversity · doi:10.1007/s11030-025-11242-2 · Cited by 6 · see citing works

Targeting cAMP signaling and phosphodiesterase 4 for liver disease treatment

Ma, J., Staller, D. W., & Mahato, R. I. (2024) · Medicinal Chemistry Research · doi:10.1007/s00044-024-03267-3 · Cited by 6 · see citing works

Phosphodiesterase 4 is overexpressed in human keloids and its inhibition reduces fibroblast activation and skin fibrosis

Milara, J., Ribera, P., Marín, S., Montero, P., Roger, I., Tenor, H., & Cortijo, J. (2024) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2024.111211 · Cited by 6 · see citing works

Non-cyclic nucleotide EPAC1 activators suppress lipopolysaccharide-regulated gene expression, signalling and intracellular communication in differentiated macrophage-like THP-1 cells

Wiejak, J., Murphy, F. A., Barker, G., Maffia, P., & Yarwood, S. J. (2024) · Cellular Signalling · doi:10.1016/j.cellsig.2024.111444 · Cited by 5 · see citing works

Proteome-wide mendelian randomization identifies causal plasma proteins in interstitial lung disease

Yu, K., Li, W., Long, W., Li, Y., Li, Y., Liao, H., & Liu, J. (2025) · Scientific Reports · doi:10.1038/s41598-025-85338-y · Cited by 4 · see citing works

Advances and future outlook in clinical trials for treating systemic sclerosis-interstitial lung disease

Jamali, M., Sanchez, R. B., Agarwal, P. P., & Khanna, D. (2025) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2025.2490729 · Cited by 4 · see citing works

Distinct cAMP Regulation in Scleroderma Lung and Skin Myofibroblasts Governs Their Dedifferentiation via p38α Inhibition

Baas, J. D., Varga, J., Feghali‐Bostwick, C. A., Peters-Golden, M. L., & Fortier, S. M. (2025) · The FASEB Journal · doi:10.1096/fj.202500694rr · Cited by 4 · see citing works

Design of an open-label extension trial of nerandomilast (BI 1015550) in patients with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis (FIBRONEER™-ON)

Wuyts, W. A., Richeldi, L., Assassi, S., Azuma, A., Cottin, V., Hoffmann‐Vold, A., Kreuter, M., Oldham, J. M., Martínez, F. J., Valenzuela, C., et al. (2025) · BMC Pulmonary Medicine · doi:10.1186/s12890-025-03973-7 · Cited by 4 · see citing works

Cardiovascular effects of Roflumilast during sepsis: Risks or benefits?

Alves, G. F., Oliveira, J. G., Nakashima, M. A., Delfrate, G., Sordi, R., Assreuy, J., da Silva‐Santos, J. E., Collino, M., & Fernandes, D. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.177015 · Cited by 4 · see citing works

What Is on the Horizon for Treatments in Idiopathic Pulmonary Fibrosis?

Moua, T., Baqir, M., & Ryu, J. H. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13216304 · Cited by 4 · see citing works

Idiopathic Pulmonary Fibrosis: 8 Years On After Nintedanib and Pirfenidone Approval—What Is on the Horizon?

Castelli, G., Cocconcelli, E., Bernardinello, N., Balestro, E., & Spagnolo, P. (2023) · Current Pulmonology Reports · doi:10.1007/s13665-023-00315-y · Cited by 4 · see citing works

Omics-Assisted Biomarkers Identification and Docking-Based Therapeutic Exploration of Moringa Phytoconstituents in Chronic Obstructive Pulmonary DiseasePreprint

Vastrad, B. M., Pattanashetti, S., & Vastrad, C. M. (2025) · Research Square · doi:10.21203/rs.3.rs-7522725/v1 · Cited by 4 · see citing works

PDE4D inhibitors: Opening a new era of PET diagnostics for Alzheimer's disease

SHI, L. ‐., Wang, X., Si, H., & Song, W. (2024) · Neurochemistry International · doi:10.1016/j.neuint.2024.105903 · Cited by 3 · see citing works

Machine Learning-Enabled Insights: Dihydromyricetin’s Novel Role in Inhibiting the TGF-β/ALK5 Signaling Cascade for the Treatment of Pulmonary Fibrosis

Dong, L., Dong, W., Ren, Y., Xu, C., Wang, X., Sun, P., Meng, Y., Li, C., Li, G., Jiang, J., et al. (2025) · Engineering · doi:10.1016/j.eng.2025.10.017 · Cited by 3 · see citing works

Artificial Intelligence-Driven Discovery of Pyrazolo[1,5- a ]pyrimidine Derivatives as Novel Phosphodiesterase 4 Inhibitors for Treating Idiopathic Pulmonary Fibrosis

Li, Z., Huan, W., Liu, X., Zhang, K., Wang, X., Huang, Y., Zhou, Q., Huang, S., Sang, Z., & Luo, H. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02407 · Cited by 3 · see citing works

Structure-based optimization of isoaurostatin as novel PDE4 inhibitors with anti-fibrotic effects

Huang, Y., Luo, X., Zhang, K., Liang, Y., Zhang, F., Liao, G., Xie, S., Huang, P.-L., Hou, S., Zhou, Q., et al. (2024) · Chinese Chemical Letters · doi:10.1016/j.cclet.2024.110586 · Cited by 3 · see citing works

Mitochondrial dysfunction-associated cellular senescence is partially involved in bleomycin-induced pulmonary fibrosis in mice

Yao, Y., Lu, X., Zhao, L., Liao, H.-Y., Liu, Z., Zhao, H., Wang, H., Xu, D., & Tan, Z.-X. (2025) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2025.117524 · Cited by 3 · see citing works

Prediction of food materials for the management of respiratory symptoms targeting PDE4B and NMDAR via machine learning approach

Jung, J., Shin, S. H., Kim, J. H., Park, J. H. Y., & Lee, K. W. (2024) · Food Bioscience · doi:10.1016/j.fbio.2024.104608 · Cited by 2 · see citing works

Emerging Concepts in Therapeutic Interventions for Idiopathic Pulmonary Fibrosis

Schott, C. A., Mohning, M. P., & Cooley, J. C. (2025) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/a-2651-1937 · Cited by 2 · see citing works

Pulmonary Vascular Endothelial Cells in Lung Diseases: Mechanisms, Therapeutic Strategies, and Future Directions

Liu, Q., Zheng, H., Liu, J., Gao, M., Lin, F., & Liao, L. (2025) · Cell Proliferation · doi:10.1111/cpr.70136 · Cited by 2 · see citing works

OSA Initiates Histone Lactylation That Drives PDE4B / FUS / AGT Axis to Pulmonary Hypertension

Yang, L., Ni, Q., He, Y., Liu, S., Gan, L., Dai, A., Hu, Y., Liu, Q., Yang, X.-C., Li, J., et al. (2025) · Cell Proliferation · doi:10.1111/cpr.70145 · Cited by 2 · see citing works

Nerandomilast attenuates idiopathic inflammatory myopathy-associated interstitial lung disease via inhibiting proliferation and differentiation of B cells

Liu, Y., Hu, Y., Se-rigeleng, Yang, Z., Liu, X., Yu, J., Li, H., Gu, S., Yang, W., Yang, C., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1771007 · Cited by 2 · see citing works

Discovery of Peripherally Restricted Indazole-Based Phosphodiesterase 4B Inhibitors Targeting the C-terminal Regulatory Helix for Treating Acute Lung Injury

Zhi, Y., Ma, D., Fan, S., Zhou, W., li, Y., Zhou, Y., Che, H., Yang, G., Sun, M., Yao, J., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03239 · Cited by 2 · see citing works

Disease Mechanisms and Therapeutic Advances in Idiopathic and Progressive Pulmonary Fibrosis: From Approved Drugs to Emerging Strategies

Tirelli, C., Muscato, G., Alaimo, C., Leo, I. D., Mirijaj, S., Pennisi, F., Vancheri, C., & Mondoni, M. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15114172 · Cited by 2 · see citing works

Discovery of kaempferol derivatives as novel PDE4 inhibitors for treatment of idiopathic pulmonary fibrosis

Cao, Y., Liao, X., Huang, P., Lu, R., Wu, Q., Zhong, K., Wang, X., Yang, Y., Liu, X., Fan, J.-J., et al. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118505 · Cited by 1 · see citing works

Diagnosis and treatment of idiopathic pulmonary fibrosis: a narrative review

Yoo, J. (2026) · Journal of Korean Medical Association · doi:10.5124/jkma.26.0044 · Cited by 1 · see citing works

Stem cell therapies for pulmonary fibrosis: emerging hope through ongoing challenges

Shi, H., Geng, R., & Liu, H. (2026) · Stem Cell Research & Therapy · doi:10.1186/s13287-025-04765-w · Cited by 1 · see citing works

PDE4 inhibitor DC591017 ameliorates pulmonary fibrosis through modulating fibroblasts-epithelial cells-alternatively activated macrophages crosstalk

Lei, S., Li, J., Yang, T., Peng, Z., Xu, Y., Hui, Z., Yan, M., Feng, C., Liu, H., & Tang, W. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.178707 · Cited by 1 · see citing works

Nerandomilast alleviates myositis-associated interstitial lung disease by modulating the non-Smad signalling pathway and activating the cAMP–PKA–RhoA pathway

Cui, X., Li, W., Chai, H., Jiang, Y., Guo, J., Yang, J., Zhu, J., & Zhang, S. W. (2026) · RMD Open · doi:10.1136/rmdopen-2025-006683 · Cited by 1 · see citing works

Nerandomilast attenuates Pantoea agglomerans-induced hypersensitivity pneumonitis by regulating M1 macrophage polarization and fibroblast activation

Shi, Y., Liu, Y. G., Liu, Z., Chen, R., Wang, M., Li, Z., Chen, Q., Shao, C., Li, X., Zhou, H., et al. (2026) · Respiratory Research · doi:10.1186/s12931-026-03721-3 · Cited by 1 · see citing works

Emerging drugs in phase 2/3 and selected phase 1/2 cellular-therapy trials: a glimpse into the future of systemic sclerosis treatment

Naveed, E., Lescoat, A., Matucci‐Cerinic, M., Kuwana, M., Denton, C. P., Allanore, Y., Pauling, J. D., Galdo, F. D., McMahan, Z., Distler, J. H. W., et al. (2026) · Annals of the Rheumatic Diseases · doi:10.1016/j.ard.2026.09.015 · Cited by 1 · see citing works

Identification of key genes and biological pathways in chronic obstructive pulmonary disease using bioinformatics and next generation sequencing data analysisPreprint

Vastrad, B. M., & Vastrad, C. M. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.10.579759 · Cited by 1 · see citing works

Reduced tracheal stenosing effect of nintedanib in a patient with scarred posttraumatic tracheal stenosis and airflow limitation - a case report

Klampfleitner, S., Fertl, A., Prinz, O., Doerfler-Schalm, M., Munker, D., & Henke, M. (2025) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2025.102168

Pneumopathies interstitielles diffuses : avancées et perspectives thérapeutiques

Jeny, F. (2025) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(25)00041-2

Structure-Based Optimization of Imidazopyridine Derivatives as Selective and Orally Bioavailable Phosphodiesterase 10A Inhibitors with Reduced Blood–Brain Barrier Penetration for the Treatment of Idiopathic Pulmonary Fibrosis

Zhang, F., Han, Y., Yao, S., Yang, D., Wu, J., Chen, J., Wang, Q., Huang, Y., Luo, H., & Guo, L. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02293

PDE4 Inhibitor Apremilast Rebalances Inflammatory Responses to Pseudomonas aeruginosa Infection in CF RatsPreprint

Antony, L., Rasmussen, L. W., Stanford, D. D., Allen, A. D., Kennedy, D., Brewer, L., Shanbhag, A., LaFontaine, J. R., & Raju, S. V. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.08.704692

Antifibrotic Strategies Targeting Phosphodiesterase-4 in Idiopathic Pulmonary Fibrosis: Molecular Mechanisms and Clinical Translation

Ma, Q., Zhou, S., Zhi, X., Luo, C., Zhu, Z., Zhang, X., & Liu, X. (2026) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s570975

Safety and Tolerability of Nintedanib in Japanese Patients with Progressive Fibrosing Interstitial Lung Diseases: Final Results of 2-Year Post-Marketing Surveillance

Ito, T., Shibuya, A., & Noguchi, H. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03502-w

Drug development in systemic sclerosis: novel therapeutics to watch

Batani, V., Colic, J., Scaletti, C., Molteni, R., Luca, G. D. D., Bandini, G., Dagna, L., Annunziato, F., Matucci‐Cerinic, M., & Campochiaro, C. (2026) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2026.2636654

Network meta-analysis of pharmacological treatments for idiopathic pulmonary fibrosis: evaluating effects on lung function

Yin, Y., Wu, X., Liu, Z., Luo, Y., Jing, M., Jing, K., Li, Q., Wang, F., & Huang, J. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1761899

Management von SARD-ILD im Wandel

Witte, T., & Schupp, J. C. (2026) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-026-01807-3

Advances in pharmacotherapy for fibrotic interstitial lung disease

Feng, X., Deng, M., Miao, J., Zheng, Z., & Hou, G. (2026) · Medical Review · doi:10.1515/mr-2025-0086

Multi-omics reveals the effects and mechanisms of Xinxue Granules against idiopathic pulmonary fibrosis through activating the cAMP/EPAC/CREB axis

Zhang, X., Li, H., Zhang, K., Shi, Y., Huang, Q., Guo, D., Zhang, X., Zhai, B., Yang, X., Luan, F., et al. (2026) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2026.122062

Machine learning integrated QSAR and molecular docking for identifying natural product derived PDE4B inhibitors in psoriatic arthritis

Raghavendra, S., Pooja, M., Kulshreshtha, R., & Priya, V. G. S. (2026) · Chemical Papers · doi:10.1007/s11696-026-05296-1

Nerandomilast mechanism of action: preferential phosphodiesterase 4B inhibition in the treatment of pulmonary fibrosis

Maher, T. M., Assassi, S., Chauffe, A., Barbera, T., Fourtouna, A., & Martínez, F. J. (2026) · Video Journal of Biomedicine · doi:10.1080/26315904.2026.2692050

PDE5 inhibitor LW1646 improves kidney fibrosis by alleviating ER stress and maintaining mitochondrial homeostasis

Wang, M., Li, M., Yuan, X., Zhao, X., Xu, L., He, J., Zhai, Q., Long, L., Zheng, Q., Zhang, H., et al. (2026) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2026.08.038

Reconfiguring the macrophage-centric intercellular network in pulmonary fibrosis: Emerging perspectives and therapeutic opportunities

Yang, Y., 刘森玉, Wang, S., Zhang, A., Wang, W., Zhu, Z., Zhang, X., & Liu, X. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108437

The emerging role of PDE4 inhibitors for the treatment of pulmonary fibrosis

Tyker, A., Kuse, N., Pertzov, B., & Kolb, M. R. (2026) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2026.2737175

Preferential phosphodiesterase inhibition as a novel strategy to modulate key pathways in systemic sclerosis

Distler, J. H. W., Frech, T., & McMahan, Z. H. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1829186

Therapie der Lungenfibrose – Beginn einer neuen Ära

Behr, J., & Veit, T. (2026) · Pneumologie · doi:10.1055/a-2959-4770

Molecular mechanisms of the Longjin Tonglin Capsule in the treatment of LPS-induced prostatic inflammation: Network pharmacology and experimental verification

Chen, C., Yang, L., Wang, Q., & Sun, T. (2026) · Letters in Drug Design & Discovery · doi:10.1016/j.lddd.2026.100587

Investigating potential prognostic genes and candidate therapeutic targets for acute myeloid leukemia in food-medicine homologous plants via integrated network pharmacology and transcriptomics

Tang, M., Chen, T., Huang, T., Bai, S., Wang, Y., Zhang, Y., Yan, L., & He, X. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05933-2

Nerandomilast treatment improves a case of progressive pulmonary fibrosis combined with severe plaque psoriasis: A case report from a clinical trial

Yang, L., & Gao, L. (2026) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666261499216

Potential of phosphodiesterase 4B inhibition in the treatment of progressive pulmonary fibrosis

Keith, R. C., & Nambiar, A. M. (2025) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666241309795 · Cited by 17 · see citing works

Antifibrotic Strategies Targeting Phosphodiesterase-4 in Idiopathic Pulmonary Fibrosis: Molecular Mechanisms and Clinical Translation

Ma, Q., Zhou, S., Zhi, X., Luo, C., Zhu, Z., Zhang, X., & Liu, X. (2026) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s570975

Potential of phosphodiesterase 4B inhibitors in the treatment of interstitial lung disease associated with autoimmune diseases

Castelino, F. V., & Adegunsoye, A. (2024) · Clinical and Experimental Rheumatology · doi:10.55563/clinexprheumatol/yg6rck · Cited by 5 · see citing works

Phosphodiesterase 4 inhibition reduces lung fibrosis following targeted type II alveolar epithelial cell injury

Sisson, T. H., Christensen, P. J., Muraki, Y., Dils, A. J., Chibucos, L. N., Subbotina, N., Tohyama, K., Horowitz, J. C., Matsuo, T., Bailie, M. B., et al. (2018) · Physiological Reports · doi:10.14814/phy2.13753 · Cited by 62 · see citing works

Rationale for phosphodiesterase-4 inhibition as a treatment strategy for interstitial lung diseases associated with rheumatic diseases

Aringer, M., Distler, O., Hoffmann‐Vold, A., Kuwana, M., Prosch, H., & Volkmann, E. R. (2024) · RMD Open · doi:10.1136/rmdopen-2024-004704 · Cited by 21 · see citing works